Exposed: 3 Cent Crypto to Explode January 20th?
Chris Rowe, the man who spotted 44 different coins that have returned over 100%, is now making the biggest crypto call of his ENTIRE career.... Because a powerful crypto event will trigger on January 20th... Sending hundreds of tiny cryptos soaring 5X, 50X, even 100X -- in just days.
Bipartisan Lawmakers Aim To Break Up Health Care Giants With New Legislation
Pharmacy-benefit managers (PBMs) have been scrutinized for their role in drug distribution for years. Now a bipartisan group of lawmakers is threatening to break up the companies behind these so-called drug middlemen.
Companies tighten security after a health care CEO's killing leads to a surge of threats
“Wanted” posters with the names and faces of health care executives have been popping up on the streets of New York. Hit lists with images of bullets are circulating online with warnings that industry leaders should be afraid.
How a Tiny 1% Use a Secret Whale CashFlow Strategy That Pays in Down Markets - Ad
How do you beat the market and earn while everyone else loses? You get paid without trading it. It's true. Using a legit "loophole" that only 1% of people in crypto even know about, you can actually get paid when other people trade.
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Corvus Pharmaceuticals shares interim Phase 1 trial data showing promising results for soquelitinib in treating moderate to severe atopic dermatitis.
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025.
Tech Funds Are Hemorrhaging Cash: Sell This Stock Now - Ad
U.S. technology funds are HEMORRHAGING cash. It's the biggest selloff since the 2022 bear market. A 50-year Wall Street veteran just explained everything you need to know. For now, he's pounding the table on the No. 1 tech stock to BUY before 2024 comes to an end... And the No. 1 tech stock Wall Street says to sell NOW.
MacKenzie Scott gives rare third gift to medical debt relief group
MacKenzie Scott continues to make medical debt relief a priority in her mysterious giving.
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events.
Set Your Alarm For 1:59 P.M. on January 31st Because THESE Stocks Set To Rocket Up - Ad
1:59 P.M. on January 31st. Set an alarm for that. Because you need to be prepared for an event that will send a certain group of stocks rocketing upward.
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials
Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to existing therapies.
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions.
"King of the Quants": Please Don't Take This Warning Lightly... - Ad
My system has recently uncovered a market phenomenon I haven't seen in 30 years.Some fortunate folks like me built generational wealth back then...while others lost their shirts and spent decades trying to recover. Well, something similar is happening today... but it will end in a much bigger way. This market shakeup is going to be much more intense.
Wisconsin's tight Republican majority sparks hope for bipartisan cooperation
MADISON, Wis. (AP) — When the Wisconsin Legislature returns to work in January, Republicans will still be in charge but will have the since taking control in 2011. That's giving Democrats, including Gov. Tony Evers, optimism that both sides will be able to work together better than they have since Evers took office six years ago.
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution
Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines.
Nixon's Revenge From Beyond the Grave - Ad
He's known as the most disgraced president in U.S. history. But there's another story about Richard Nixon... a totally different story from 51 years ago... that you haven't been told... that would have made him a true American hero forever. Now... in a strange twist of fate... this same story could also give investors the chance to become wealthy beyond compare starting in 2025.
An Alabama woman is doing well after the latest experimental pig kidney transplant
NEW YORK (AP) — An Alabama woman is recovering well after a last month that freed her from eight years of dialysis, the latest effort to save human lives with animal organs.
Nuclear bunker sales increase, despite expert warnings they aren’t going to provide protection
When Bernard Jones Jr. and his wife, Doris, built their dream home, they didn’t hold back. A grotto swimming pool with a waterfall for hot summer days. A home theater for cozy winter nights. A fruit orchard to harvest in fall. And a vast underground bunker in case disaster strikes.
My TOP Altcoin for Right Now Is... - Ad
Searching for the top investment opportunity in crypto? Look no further. Our $3 report gives you the full scoop. You'll get this exciting token's name, our recommended investment strategy, and growth projections. Time is of the essence with this one...
Owner of thermometer factory gets probation for exposing workers to mercury
WEST BABYLON, N.Y. (AP) — The owner of a New York thermometer factory was sentenced Friday to three years of probation for failing to protect workers who were exposed to hazardous levels of mercury after a spill at his plant.
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.
Man Who Called Nvidia Says "Buy These Five AI Stocks." - Ad
In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company...And the stock is up massively since Jeff's recommendation. Now, Jeff has found five under-the-radar stocks which could power your retirement. And it's in large part because these companies are connected to Elon Musk and Nvidia.
McKinsey & Company agrees to pay $650 million to settle federal probe over opioids work
WASHINGTON (AP) — McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer , according to court papers filed in Virginia on Friday.
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing.
Trump's New "AI Economy" Could Mint 22,000 New American Millionaires Every 30 Days - Ad
A tidal wave of new AI wealth is about to flow into the economy. However, the biggest gains may no longer come from the usual hot AI stocks you've been hearing lately. We reveal how you can get the names of all the stocks you should get into now for the biggest investment opportunities of your life.
Fewer U.S. grandparents are taking care of grandchildren, according to new data
Fewer grandparents were living with and taking care of grandchildren, there was a decline in young children going to preschool and more people stayed put in their homes in the first part of the 2020s compared to the last part of the 2010s, according to U.S. Census Bureau data released Thursday, reflecting some of the effects of .
In Nigeria's lithium boom, many mines are illegal and children do much of the work
NASARAWA, Nigeria (AP) — Dressed in a faded pink dress, 6-year-old Juliet Samaniya squats under scorching skies to chip at a jagged white rock with a stone tool. Dust coats her tiny hands and her hair as she works hour after hour for less than a dollar a day. The landscape around her is dotted with active and abandoned mineshafts, farmland that may soon be cleared in search of more rich ore, and other mine workers — many of them children.
Sell Nothing. Retire Early. Mission Complete. - Ad
What if you could retire in 3 years instead of 10-15? While everyone is trying to trade the market and gamble on poop coins and meme coins, some people are using a little known method to actually earn passive returns. We probably have 3 years to exploit this before the party is over. That's plenty of time to retire early in crypto.
Man accused of killing UnitedHealthcare's CEO shouts on way into courthouse and fights extradition
ALTOONA, Pa. (AP) — The man charged with murder in the killing of the made it clear he wasn’t going to make things easy on authorities, shouting unintelligibly and writhing in the grip of sheriff’s deputies as he was led into court and then objecting to being brought to New York to face trial.
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
Eli Lilly announces $15 billion share buyback plan and 15% dividend boost amidst mixed technical signals. Investors are skeptical.
There's Only ONE AI Company That Matters - Ad
It's not Nvidia, AMD, IBM, or any new startup. It's not even an artificial intelligence company... yet it holds the key to the entire AI market. Get all the details of the critical technology that the entire AI sector needs to survive.
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Jefferies upgrades Vertex Pharmaceuticals to Buy, highlighting a promising pipeline and $5 billion-$7 billion growth potential from pain and kidney treatments.
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.
Did You See Trump's Bombshell Exec. Order 001? - Ad
Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." It's a bombshell law that Trump could sign within minutes of stepping into the Oval Office... And it will instantly set off the most sweeping government technology project in 80 years... The most lucrative, too...
USDA orders nationwide testing of milk for bird flu to halt the virus
The U.S. government on Friday ordered testing of the nation's milk supply for bird flu to better monitor the spread of the virus in dairy cows.
Why Is BioNTech Stock Trading Higher On Friday?
BNT324/DB-1311 trial data show significant antitumor activity in various cancers, with high response rates in small cell lung and prostate cancer patients.
Trump's Legacy-Defining Moment to Strike - Ad
Elon Musk predicts historic crisis in first year of Trump's presidency. but the surprising way trump solves it could cement his legacy.
Michigan Democrats move to protect reproductive health data before GOP takes control of House
LANSING, Mich. (AP) — Michigan Democrats are pushing this month to pass legislation they say will improve reproductive health care, in particular the safety of , ahead of .
Anthem Blue Cross Blue Shield reverses decision to put a time limit on anesthesia
One of the country’s largest health insurers reversed a change in policy Thursday after widespread outcry, saying it would not tie payments in some states to the length of time a patient went under anesthesia.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.